AU Patent

AU2016250419B2 — 1' -substituted carba-nucleoside analogs for antiviral treatment

Assigned to Gilead Sciences Inc · Expires 2018-08-09 · 8y expired

What this patent protects

Provided are pyrrolo[ 1,2-fl [1,2,4]triazinyl, imidazo[ 1,5-fl [1,2,4]triazinyl, imidazo[ 1,2 f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the I 'position of the nucleoside sugar is substituted. Th…

USPTO Abstract

Provided are pyrrolo[ 1,2-fl [1,2,4]triazinyl, imidazo[ 1,5-fl [1,2,4]triazinyl, imidazo[ 1,2 f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the I 'position of the nucleoside sugar is substituted. The 5 compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. Formula (I), each X or X2 is independently C-R 10or N. Fonnula I

Drugs covered by this patent

Patent Metadata

Patent number
AU2016250419B2
Jurisdiction
AU
Classification
—
Expires
2018-08-09
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.